News Acquisitive Ipsen builds again with $952m Albireo buy French drugmaker Ipsen has continued a recent spate of deal-making with a $42-per-share offer to buy US biotech Albireo and its rare disease therapy Bylvay.
Views & Analysis Q&A: Albireo’s Ron Cooper on bile acid modulation While bile acids might not be as trendy as gene editing, modulating them has potential for first-in-class therapies for liver diseases.
News 'Trust gap' is holding back AI in healthcare The potential for AI to help tackle bottlenecks in healthcare is being held back by patient scepticism and doctor concerns about bias and liability.
Market Access Sponsored Bridging research and clinical guidelines – interactive stra... Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.